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SAFETY COSTS OF IPLEDGE WITH THE EFFICACY OF 
ACCUTANE (ISOTRETINOIN) 
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The Food and Drug Administration (“FDA” “Agency”) continues 
to face one of the most intractable issues of its tenure: deciding 
whether and when efficacious treatments that may harm fetuses 
should be available on the market.1  Currently, the Agency weighs the 
benefits of such medication with the risk of fetal malformation, fac-
toring the expected reduction of risk accomplished with the utiliza-
tion of risk management programs.2  These risk management pro-
grams seek to decrease the occurrence of fetal exposure by 
facilitating the distribution of educational materials and limiting drug 
access among women of child-bearing age.3  This is best illustrated by 
the current debate raging within medical circles regarding the FDA’s 
decision to allow Accutane and its generic equivalents4 to remain on 
the market, while attempting the third in a series of flawed risk man-
agement programs to prevent the birth of children with disabilities 
due to drug exposure.  As implemented, the Accutane risk manage-
ment program is inadequate to accomplish its goals of eliminating fe-
tal exposure, and represents an unacceptable incursion on women’s 
autonomy to decide the course of their medical care.  Consequently, 
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 1 See JEFFERY E. FETTERMAN ET AL., A FRAMEWORK FOR PHARMACEUTICAL RISK 
MANAGEMENT 7 (Food and Drug Law Institute 2003). 
 2 Id. 
 3 Id. at 7, 8. 
 4 Throughout this Comment Accutane and its generic equivalents are collec-
tively referred to as Accutane or isotretinoin.  Since Accutane did not have generic 
competition until the implementation of the S.M.A.R.T. risk management program, 
the use of Accutane, instead of the generic name isotretinoin, after the introduction 
of generics is done solely to avoid confusion. 
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the FDA should remove Accutane and its generic equivalents from 
the market. 
Some medications present such a serious risk to fetuses that the 
FDA has advised manufacturers to provide warnings accompanying 
the medication to ensure that pregnant women or those of child-
bearing age do not take or come in contact with the drug.5  Labeling 
warnings on products is just one mechanism advocated by the FDA to 
manage risk through educating patients about the drug’s effect in 
pregnancy.6  For example, Propecia, which treats hair loss in men, 
has such a high potential for mutative effects in fetuses that prescrip-
tion bottles contain warnings alerting women who may be pregnant 
to avoid handling the medication if tablets are broken.7
Recently, the FDA has approved much more aggressive and for-
malized risk management programs like S.T.E.P.S., A System for Tha-
lidomide Education and Prescribing Safety, to ensure the safety of 
pregnant women and women of child-bearing potential.8  Thalido-
 5 See FETTERMAN, supra note 1.  Medications known to be teratogens and there-
fore contra-indicated in pregnancy include: androgens, anticonvulsants, antineoplas-
tics, diethlystillbestol, etretinate, iodides, isotretinoin, lithium, live vaccines, methi-
mazole, penicillamine, tetracyclines, and warfarin.  JOSEPH T. DIPIRO, ET AL., 
PHARMACOTHERAPY 1302 (4th ed. 1999).  Medications suggested to be teratogens and 
therefore have warnings against use in pregnancy include: angiotension converting 
enzyme inhibitors (ACE-I), benzodiazepines, estrogens, oral hypoglycemics, pro-
gestogens, and quinolones. The FDA has approved these medications with warnings, 
concerning their risk in pregnancy.  Id. 
 6 See FETTERMAN, supra note 1. 
 7 CHARLES F. LACY, ET AL., DRUG INFORMATION HANDBOOK 481 (Lexi-Comp 2001); 
Merck, Propecia homepage, http://www.propecia.com (last visited Jan. 3, 2007).  
Propecia (Finasteride) is a medication useful in the treatment of male pattern bald-
ness. Id. 
Women who are or may potentially be pregnant must not use Propecia 
and should not handle crushed or broken Propecia tablets because the 
active ingredient may cause abnormalities of a male baby’s sex organs. 
If a woman who is pregnant comes into contact with the active ingredi-
ent in Propecia, a doctor should be consulted.  Propecia tablets are 
coated and will prevent contact with the active ingredient during nor-
mal handling, provided that the tablets are not broken or crushed. 
Merck, Propecia homepage, http://www.propecia.com (last visited Jan. 3, 2007).
 8 Center for Drug Evaluation and Research, FDA Announces Approval of Drug 
for Hansen’s Disease (Leprosy) Side Effect; Imposes Unprecedented Authority to 
Restrict Distribution, http://www.fda.gov/cder/news/thalinfo/ (last visited Jan. 9, 
2007). 
On July 16, 1998, FDA approved the use of thalidomide for the treat-
ment of the debilitating and disfiguring lesions associated with ery-
thema nodosum leprosum (ENL), a complication of Hansen’s Disease, 
commonly known as leprosy.  Because of thalidomide’s potential for 
causing birth defects, FDA invoked unprecedented regulatory authority 
to tightly control the marketing of thalidomide in the United States.  A 
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mide was first marketed in Western Europe in the late 1950s for the 
treatment of morning sickness in pregnancy and for use as a sleeping 
pill.9  At the time, its teratogenic effect was unknown until women 
exposed to the medication delivered infants with horrific birth de-
fects, including mutation of limbs.10  The FDA immediately denied 
approval of this drug for marketing in the United States.11  In re-
sponse to the appalling effects of Thalidomide, Congress enacted leg-
islation requiring pharmaceutical manufactures to prove the efficacy 
of a drug product to obtain FDA approval.12
In a remarkable turn around, in 1998 the FDA approved Tha-
lidomide for the treatment of lesions associated with leprosy.13  The 
FDA conditioned approval upon the manufacturer’s implementation 
of S.T.E.P.S.,14 a stringent risk management program that includes 
requiring female patients of reproductive age to undergo pregnancy 
testing and contraception counseling, the company to maintain a pa-
tient registry, and manufacturers to control distribution to authorized 
prescribers and pharmacies.15  Thalidomide’s resurgence epitomizes 
the challenge of balancing risks and benefits of efficacious treatments 
that carry significant safety risks. 
System for Thalidomide Education and Prescribing Safety (S.T.E.P.S) 
oversight program has been initiated that includes limiting authorized 
prescribers and pharmacies, extensive patient education about the risks 
associated with thalidomide and a 100% patient registry.  This over-
sight program is designed to help insure a zero tolerance policy for 
thalidomide exposure during pregnancy. 
Id. 
 9 Center for Drug Evaluation and Research, Frequently Asked Questions and 
Answers about Thalidomide, http:/www.fda.gov/cder/news/thalinfo/ (last visited 
Jan. 9, 2007). 
 10 See Janet Woodcock, FDA’s Medical Review of Thalidomide Clinical Develop-
ment, http://www.fda.gov/cder/news/thalinfo/20785medr.htm (last visited Jan. 9, 
2007). 
 11 Id. 
 12 Id.  Kefauver-Harris Drug Amendments passed to ensure that a drug was not 
only safe for human use but also effective in treating a proposed indication.  Id.  For 
the first time, drug manufacturers were required to prove to FDA the effectiveness of 
their products before marketing them.  Id. 
 13 Center for Drug Evaluation and Research, supra note 8. 
 14 Letter from Murray M. Lumpkin, Deputy Center Dir., Center for Drug Eval. 
and Research, to Steve Thomas, Celgene Corporation (July 16, 1998) (on file with 
the FDA), available at http://www.fda.gov/cder/foi/appletter/1998/20785ltr.pdf. 
 15 Memorandum from Carl Kraus, Medical Officer, Division of Special Pathogen 
and Immunologic Drug Products, to Anne Trontell, Deputy Director, Office of Drug 
Safety at the Department of Health and Human Services (Jan. 29, 2004) (on file with 
the FDA), available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/4017B1-
06b%20Overview%20STEPS%20Section%20C%20Tab%207.pdf. 
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And yet, the FDA’s approach only manages risk; it does not 
eliminate it.  In the same year that the FDA approved S.T.E.P.S, the 
Agency also permitted the introduction of Accutane, a drug used to 
treat severe acne but shown to cause birth defects.16  Six years after 
market introduction, Accutane’s manufacturer, Hoffman-La Roche, 
designed the Pregnancy Prevention Program (“PPP”) to prevent 
pregnancy exposures from Accutane in response to concerns about 
birth defects.17  PPP required disbursement of educational materials 
about avoiding pregnancy while on the medication, periodic preg-
nancy testing, and evidence of contraceptive use or abstinence by fe-
males of child-bearing age.18  The program did not yet include a man-
datory patient registry or controlled distribution like S.T.E.P.S.19  The 
inadequacy of these precautions is poignantly illustrated by events 
that occurred in 1999, when a twenty-five year old woman obtained a 
prescription for Accutane from her dermatologist for treatment of se-
vere acne.20  The patient began Accutane therapy without waiting for 
menstruation, as indicated in the patient literature about the pro-
gram requirements for women of reproductive age.21  Despite having 
had a negative pregnancy test before starting the medication and us-
ing two forms of contraception during sexual intercourse, the patient 
had a positive pregnancy test after taking the medication for one 
month.22  Her infant was born with multiple anomalies.23  After car-
diac surgery and extensive medical treatment for nine weeks, the in-
fant died.24
 16 See Woodcock, supra note 10. 
 17 See FDA, Background of Isotretinoin Teratogenic Risk Management Plan at 1, 
http://www.fda.gov/ohrms/dockets/ac/04/briefing/4017B1-
02%20%20AC%20Intro%20Review%20-Section%20A%20Tab1.pdf (last visited Jan. 
9, 2007) [hereinafter Background of Isotretinoin]; see Eileen Enny Leach, MPH, 
Targeted Pregnancy Prevention Program for Women on Accutane, Presentation to 
the FDA (Sept. 18, 2000) available at http://www.fda.gov/ohrms/dockets/ac/ 
00/slides/3639s1j.ppt.. 
 18 Leach, supra note 17. 
 19 Id. 
 20 See Accutane-Exposed Pregnancies—California 1999, 49 MORBIDITY & MORTALITY 
WKLY. REP. 28, 30–31 (Jan. 21, 2000) [hereinafter Accutane-Exposed]. 
 21 Id. at 29–31.  Waiting until menstruation before initiating treatment is a pre-
ventative measure to confirm a woman has not conceived from the time of her preg-
nancy test to the first day of therapy.  Id.  
 22 Id. 
 23 Id. 
 24 Id. 
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This case, which is one of many,25 illustrates the grave conse-
quences of a risk management program that fails.  Failures occur 
most frequently because of noncompliance by the patient who ne-
glected to read the program information and by the physician who 
did not counsel the patient on the program requirements.26  Impos-
ing even greater restrictions to avoid knowingly giving birth to a child 
with severe deformities due to drug exposure creates a proverbial 
Gordian knot—how does one create a program that grants access to a 
life-changing drug, while simultaneously regulating its use to prevent 
the occurrence of fetal exposure?27
This Comment analyzes the FDA’s reliance on risk management 
programs to balance public health with patients’ access to medical 
innovation by focusing on the most recent iteration of such pro-
grams, iPLEDGE for Accutane and its generic equivalents.  Part I of 
this Comment provides a general review of Accutane’s FDA approval 
history, reports of fetal harm from exposure to the drug, and past Ac-
cutane risk management programs that failed to sufficiently minimize 
fetal exposure.  Part II is broken into two sections discussing the so-
cial and safety costs of the iPLEDGE program.  The first section ex-
amines the program’s implications for women of child-bearing poten-
tial.  This section provides a brief history of limiting women’s health 
care decisions based on child-bearing age and then analyzes how 
iPLEDGE provisions affect such women.  The second section dis-
cusses the safety implications of iPLEDGE, specifically illustrating 
how this program will not achieve the goal set by the FDA to elimi-
nate pregnancy exposures to Accutane.  Finally, Part III concludes 
that iPLEDGE is inadequate for fulfilling the FDA’s role in protecting 
public health by permitting access to unsafe medication under the 
guise of a counterproductive and intrusive monitoring program.  
Having Accutane available on the market has great social and safety 
costs that outweigh its effectiveness in treating severe acne.  There-
fore, the medication should not be available to the general public.  
The FDA should not allow flawed risk management systems to mask a 
manufacturer’s inability to produce a safe product. 
 25 See e.g. Accutane-Exposed, supra note 20; M.A. Honein, et. al., Continued Occur-
rence of Accutane-Exposed Pregnancies, 64 TERATOLOGY 142, 143 (2001). 
 26 Accutane-Exposed, supra note 20; Continued Occurrence of Accutane-Exposed Preg-
nancies, supra note 25, at 143. 
 27 See Bernadine Healy, Pledging for Accutane, U.S. NEWS & WORLD REP., Sept. 5, 
2005, at 63;  Laurel N. Geraghty, Doctors Fear Acne Drug Rules Go Too Far, N.Y. TIMES, 
Jan. 12, 2006. 
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I. AN OVERVIEW OF ACCUTANE’S APPROVAL HISTORY 
In 1982, the FDA approved Hoffman-La Roche’s (“Roche”) Ac-
cutane for the treatment of severe nodular acne.28  This type of acne 
produces cysts on the face and body from bacteria developing in in-
creased numbers, stimulating the inflammatory process, and produc-
ing lesions with a diameter of five millimeters or greater, which can 
produce severe scarring.29  The duration of Accutane treatment is fif-
teen to twenty weeks and results in partial to complete remission of 
cyst-forming acne.30  From 1982-2000, over five million Americans 
took Accutane, with 19.8 million prescriptions dispensed from 
United States pharmacies.31  Since that time, generic versions of the 
drug have been on the market, resulting in lower prices and greater 
accessibility.32  While even severe acne is undeniably far from a life 
threatening condition, Congress heard testimony in 2002 while inves-
tigating the safety of Accutane that illustrated how life altering this 
treatment has been for patients.33  Some patients referred to the 
medication as a “miracle drug.”34  A former Accutane patient, David 
Shove, recounted: 
 28 Center for Drug Evaluation and Research, Label and Approval History of Ac-
cutane (Isotretinoin) NDA #018662, http://www.accessdata.fda.gov/scripts/cder/ 
drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (last visited 
Jan. 9, 2007) (approval occurred on May 7, 1982). 
 29 Id. 
 30 Id. 
 31 Diane K. Wysowski et al., Use of Isotretinoin (Accutane) in the United States: Rapid 
Increase from 1992 through 2000, 46 J. AM. ACAD. DERMATOLOGY 505, 506 (2002);  
Mitchell et al., An Assessment of the Accutane Pregnancy Prevention Program, Pres-
entation at the FDA Dermatologic Drugs Advisory Committee Meeting (Sept. 18, 
2000). 
 32 Center for Drug Evaluation and Research, Therapeutic Equivalents of Accu-
tane (Isotretinoin) NDA #018662, http://www.accessdata.fda.gov/scripts/cder/ 
drugsatfda/index.cfm?fuseaction=Search.Generics (last visited Jan. 9, 2007).  There 
are currently three generic versions of Accutane, which all have the same active in-
gredient isotretinoin.  Id.  These generic products include: Amnesteem manufac-
tured by Genpharm, FDA approval on Nov. 8, 2002; Claravis manufactured by Barr, 
FDA approval on Apr. 11, 2003; and Sotret manufactured by Ranbaxy, FDA approval 
on Dec. 24. 2002, Jun. 20, 2003.  Id.  
 33 Issues Relating to the Safety of Accutane: Hearing Before the Subcomm. on Oversight 
and Investigations of the H. Comm. on Energy and Commerce, 107th Cong. 107–143 (2002) 
(The investigation of Accutane by the Subcommittee was prompted after reports of 
birth defects, depression and suicides related the drug’s use.  Representative Stupak, 
member, House Comm. on Energy and Commerce, lost his son from suicide, possi-
bly related to Accutane use.). 
 34 Id. (statement by Dr. Diane S. Berson, Associate Director of Dermatology at 
Cornell University). 
     Accutane has been called a “miracle drug” by many patients who 
have suffered from the pain and embarrassment of acne.  It has 
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     I endured severe acne during my high school years. . . . I was 
fixated upon the idea that my classmates were consumed by my 
“freakish” appearance.  I was embarrassed at times to be seen.  I 
avoided all cameras . . . and image capturing experiences.  I re-
frained from attending events during the most heinous of break-
outs.  I loathed the idea of presenting in front of any type of 
group. . . .  While all these ideas may seem simple and, in the 
grand scheme of the universe, unimportant, I assure you to a 17-
year-old growing up, one’s physical appearance is life-defining.  
Accutane does not grow self-confidence genes, it does not develop 
assertiveness cells, it simply clears one’s skin.  It is through this ba-
sic task, that Accutane did, in fact, change my life.35
A. Risk Management from Accutane Drug Approval to S.M.A.R.T. 
(1982-2000) 
The FDA first reviewed Accutane’s clinical data in 1981 when 
Roche filed a New Drug Application (NDA).36  At this time, Roche 
submitted animal testing data to the FDA illustrating birth defects in 
animal offspring.37  In addition, the manufacturer reported no hu-
man birth defects in clinical trials.38  As a result, the manufacturer 
recommended that warnings be included within Accutane labeling 
cautioning women about this possible side effect.39  However, the 
changed the lives of so many young adults who were forced to avoid in-
teractions with their peers at the very age when association awareness 
peaks.   
     In the last 15 years I have prescribed Accutane to hundreds of pa-
tients.  So many individuals are grateful that I was able to offer them 
medication which cleared a condition many had suffered with for years 
. . . . 
Id. 
 35 Id. (statement of David Shove, former Accutane patient). 
 36 Center for Drug Evaluation and Research, supra note 28. 
 37 Jill Riepenhoff & Mark D. Somerson, Company Soft-Pedaled Accutane Tie to Birth 
Defects in 1982, COLUMBUS DISPATCH, May 19, 1996, at 2D. 
 38 Id.  
 39  Id.  Roche recommended approval of Accutane labeling with a Pregnancy 
category C designation. Id.  Pregnancy category C is used “[i]f animal reproduction 
studies have shown an adverse effect on the fetus, if there are no adequate and well-
controlled studies in humans, and if the benefits from the use of the drug in preg-
nant women may be acceptable despite its potential risks.”  21 C.F.R. § 
201.57(c)(9)(i)(A)(3). Pregnancy category A is used “[i]f adequate and well-
controlled studies in pregnant women have failed to demonstrate a risk to the fetus 
in the first trimester of pregnancy (and there is no evidence of a risk in later trimes-
ters) . . . .” 21 C.F.R. § 201.57(c)(9)(i)(A)(1) (2006). Pregnancy category B is used 
“[i]f animal reproduction studies have failed to demonstrate a risk to the fetus and 
there are no adequate and well-controlled studies in pregnant women . . . .” 21 C.F.R. 
§ 201.57(c)(9)(A)(2). Pregnancy category D is used “[i]f there is positive evidence of 
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manufacturer failed to inform the Agency of the precautions taken to 
avoid pregnancy exposure in the clinical trials.40  Some clinical trials 
excluded women completely while others required women to be on 
oral contraception and undergo pregnancy testing.41  One woman 
became pregnant but decided to have an abortion.42  Unaware of 
these details, the FDA made no additions to the label educating 
women about the details of these clinical trials.43  The FDA did refer 
the animal testing data to its Dermatologic Drugs Advisory Commit-
tee (now called the Dermatology and Ophthalmic Drugs Advisory 
Committee) to recommend additional pregnancy warnings.44
After reviewing the NDA and referring it to an advisory commit-
tee, the Agency approved the medication after only nine months.  
Due to the drug’s effectiveness in the treatment of severe acne, the 
FDA accelerated the approval process.45  Consequently, Accutane was 
approved in 1982.46  The drug was designated a pregnancy category X 
medication, an FDA code indicating that the risk of the drug in 
pregnancy outweighs any benefit it may have.47
human fetal risk based on ad-verse reaction data from investigational or marketing 
experience or studies in humans, but the potential benefits from the use of the drug 
in pregnant women may be acceptable despite its potential risks (for example, if the 
drug is needed in a life-threatening situation or serious disease for which safer drugs 
cannot be used or are ineffective) . . . .” 21 C.F.R. § 201.57(c)(9)(A)(4). Finally, 
pregnancy category X is used “[i]f studies in animals or humans have demonstrated 
fetal abnormalities or if there is positive evidence of fetal risk based on adverse reac-
tion reports from investigational or marketing experience, or both, and the risk of 
the use of the drug in a pregnant woman clearly outweighs any possible benefit (for 
example, safer drugs or other forms of therapy are available) . . . .” 21 C.F.R. § 
201.57(c)(9)(A)(5). 
 40 Riepenhoff  & Somerson, supra note 37, at 2D. 
 41 Id. 
 42 Jill Riepenhoff & Mark D. Somerson, Patient was Urged to Get an Abortion; Re-
searcher Feared Defects in Accutane User’s Baby, COLUMBUS DISPATCH, April 8, 1996, at 1C. 
 43 Background of Isotretinoin, supra note 17, at 1. 
 44 Dr. Colonel Evans, FDA Medical Group Leader, Speaker at the Dermatologic 
Drugs Advisory Committee Open Session (May 8, 1989) (transcript available at 
http://www.fda.gov/ohrms/dockets/ac/accutane/29t1.pdf). 
 45 Penny Chorlton, FDA Outpaced Firm on Acne Drug, WASH. POST, Sept. 13, 1982, 
at 56 (Accutane had been classified by the FDA as “1A,” meaning it was top priority 
for approval.  The quick turnaround time from submission of NDA to approval sur-
prised Roche who took an extra four months to prepare the drug for launch to the 
public.). 
 46 Center for Drug Evaluation and Research, supra note 28 (approval occurred on 
May 7, 1982). 
 47 Background of Isotretinoin, supra note 17, at 1; 21 C.F.R. § 201.57(c)(9)(A)(1-
4). 
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Shortly thereafter, the company received voluntary reports of 
pregnancy from Accutane users and disclosed the cases to the FDA.48  
Consequently, the FDA advised Roche to make additions to preg-
nancy warnings, which included sending “Dear Doctor” letters and 
creating red warning stickers to be used at pharmacies to alert pa-
tients of the pregnancy risk.49  Despite the effort to bolster patient 
warnings and make reports to doctors, the manufacturer and the 
FDA continued documenting instances of infants being born with 
Accutane embryopathy malformations.50
For example, in February of 1988, Dr. Godfrey Oakley wrote the 
FDA stating, 
     I know that because the product is effective against cystic acne 
that removing the drug from the market will not be popular.  On 
the other hand, I know that 40 infants born alive after the first 
trimester exposure to Accutane have died as infants or children 
because of the developmental errors that Accutane caused.  I be-
lieve if 40 teenagers or young adults with acne had died as a result 
of therapy caused by this drug that the drug would [be] viewed as 
too dangerous, even though effective, to be on the market.51
 48 Memorandum from Dr. Edward Lammer, FDA Epidemic Intelligence Service 
(EIS) Officer, to Drs. Godfrey P. Oakley and Jose Cordero, Centers for Disease Con-
trol staff (July 29, 1983) (on file with the FDA), available at 
http://energycommerce.house.gov/107/hearings/12112002Hearing755/2.pdf.  
The memorandum entitled “The Record (Teratology File)” describes how the FDA 
spoke with Roche and received reports of four cases of children born with malforma-
tions from mothers who had taken Accutane in the first trimester.  The record also 
documented that though Roche reported in November of 1982 that: 
no fetal abnormalities were reported in the Accutane clinical trials, in 
fact there were no outcomes to evaluate.  Of the 4 pregnancies occur-
ring during the trials, 2 women elected to abort their fetuses, one child 
was dead at 26 weeks gestation secondary to a prolapsed cord, and one 
child was delivered at term and was normal.  Retrospectively, it was de-
termined that this latter mother was noncompliant and never took the 
drug during her pregnancy. 
Id.  This document is then followed by countless letters from doctors asking the FDA 
to pull the drug off the market.  Id. 
 49 Background of Isotretinoin, supra note 17, at 1.  FDA “Dear Doctor” letters are 
letters mailed to physicians highlighting specific information a prescriber should be 
aware of concerning a medication.  See FDA, Manual of Standard Operating Proce-
dures and Policies, SOPP 8108, http://www.fda.gov/cber/regsopp/8108.htm (last 
visited Jan. 7, 2007).  Usually specific warnings or contraindications are emphasized 
in these letters.  Id.  
 50 Center for Disease Control and Prevention (CDC), Current Trends Birth Defects 
Caused by Isotretinoin—New Jersey, 37 MORBIDITY & MORTALITY WKLY. REP. 171–72, 177 
(1988) (Embryopathy includes craniofacial, cardiac, thymic, and central nervous sys-
tem malformations). 
 51 Letter from Dr. Godfrey P. Oakley, Jr., Dir. of Div. of Birth Defects & Devel-
opmental Disabilities Ctr. for Envtl. Health and Injury Control, Ctrs. for Disease Con-
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In addition, Dr. J. David Erickson wrote a letter to the FDA illustrat-
ing the concerns of the medical community and questioning the 
FDA’s rationale in allowing Accutane to remain on the market.52  In 
his letter he asked, “I would like to know what procedures were fol-
lowed to arrive at an accounting of the benefits and risks of the use of 
these drugs.”53
Consequently, the FDA Dermatologic Drugs Advisory Committee 
met on April 26, 1988 to discuss the reaction to reports of fetal expo-
sure and abortions associated with the use of Accutane.54  At this 
meeting, the FDA reported knowing of sixty-two birth defects attrib-
uted to Accutane and presented evidence suggesting that the drug 
was being used by thousands of women of child-bearing potential 
with less than severe acne.55  As a result, the committee recom-
mended the FDA restrict the drug’s use in one or more of the follow-
ing ways: dispensing only to certain physicians, placing restrictions on 
medication access, or requiring educational programs for physicians 
to dispense the drug.56  Following this meeting, the FDA suggested “a 
number of interventions [to Roche] the purposes of which were 1) 
elimination of pregnancy exposure and 2) reduction of product us-
age to that specified in the labeling.”57
After discussions with the FDA concerning the advisory commit-
tee’s suggestions, Roche introduced the PPP in 1988.58  This program 
comprised of package warning labels, an informed consent form, an 
informational kit for prescribers, a tracking study to access prescrib-
ers’ use of the kit, and a voluntary patient enrollment survey (the Bos-
trol, to Dr. Gerald Faich, FDA staff (Feb. 1, 1988) (on file with the FDA), available at 
http://energycommerce.house.gov/107/hearings/12112002Hearing755/3.pdf. 
 52 Letter from Dr. J. David Erickson, Chief, Birth Defects and Genetic Diseases 
Branch, Div. of Birth Defects & Developmental Disabilities at the Ctr. for Envtl. 
Health and Injury Control, Ctrs. for Disease Control, to Dr. James Bilstad, FDA Staff 
(Mar. 17, 1988) (on file with the FDA), available at http://energycommerce. 
house.gov/107/hearings/12112002Hearing755/4.pdf. 
 53 Id. 
 54 FDA, Isotretinoin (Accutane) Birth Defects Update at 1, Apr. 26, 1988, 
http://www.fda.gov/bbs/topics/ANSWERS/ANS00247.html (last visited Jan. 9, 
2007). 
 55 Id. at 1. 
 56 Id. at 2.  
 57 Memorandum from Dr. David J. Graham, Medical Epidemiologist, Accutane 
Monitoring Group, Dep’t of Health and Human Services, to the Chairman of the Ac-
cutane Monitoring Group, Dep’t of Health and Human Ser. at 1 (Apr. 6, 1989) (on 
file with the FDA), available at http://energycommerce.house.gov/107/hearings/ 
12112002Hearing755/9.pdf. 
 58 Leach, supra note 17, at 1; Background of Isotretinoin, supra note 17, at 1. 
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ton University Accutane Survey)59 to assess compliance with the pro-
gram.60  The change in the medication’s labeling required women of 
child-bearing potential desiring a prescription for Accutane to com-
mit either to abstaining from sexual intercourse, or to using two 
methods of effective contraception simultaneously, to have a negative 
pregnancy test before starting Accutane, and to wait until the second 
or third day of their next menstrual period before beginning to take 
Accutane.61  In addition, women were required to undergo monthly 
pregnancy testing and monthly contraceptive counseling while on 
Accutane therapy.62  Doctors could only prescribe a month supply of 
Accutane to enforce continued evaluation and counseling of pa-
tients.63
Yet, even with this program, reports of fetal exposure to Accu-
tane continued.  In an April 1989 FDA memorandum, Dr. David 
Graham reported the incidence of pregnancy exposure based on re-
ports of at least one pregnancy per 2000 women of reproductive 
age.64  Dr. Graham also acknowledged FDA discrepancies in preg-
nancy exposure data—“the FDA learned only a fraction of actual first 
trimester pregnancy exposure events.”65  Furthermore, Graham ob-
served that such underreporting is common with Accutane because 
“the majority of Accutane pregnancy exposures end with either spon-
taneous or induced abortion and physicians do not customarily re-
port such outcomes as adverse drug reactions.”66  In addition, Dr. 
Graham articulated concern about the lack of effective, post-
marketing studies by Roche to evaluate the effectiveness of the new 
labeling change.67
A year later, Dr. Graham reported the past two years illustrate 
“that intensive regulation has not, cannot and will not achieve the 
 59 Allen A. Mitchell et al., A Pregnancy-Prevention Program in Women of Childbearing 
Age Receiving Isotretinoin, 333 NEW ENG. J. MED. 101, 101–05 (July 1995) (summarizing 
the Boston University Accutane Survey also referred to as the Slone Survey). 
 60 Leach, supra note 17. Accutane was packaged in blister packages of ten, twenty, 
and forty milligram tablets with an “avoid pregnancy logo at each pill site.”  Id.  The 
package also included the black box warning concerning birth defects and line draw-
ings of birth defects.  Id. 
 61 Id.  This is to assure that the woman is not pregnant.  Id.  
 62 Id. 
 63 Leach, supra note 17.  
 64 Graham, supra note 57, at 1. 
 65 Id. at 7. 
 66 Id. 
 67 Id. at 8. 
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Agency’s goal of eliminating pregnancy exposure to Accutane.”68  He 
further argued that the drug should be immediately removed from 
the market citing that in the past year “while the Agency waited for 
more complete data on the effect of its interventions to accumulate, 
an additional 1900 pregnancy exposures occurred with 1500 abor-
tions and 117 children with birth defects.”69  Despite this memoran-
dum and pressure from other medical research groups, including the 
Centers for Disease Control and Prevention advocating the removal 
of Accutane from the market, the FDA continued discussions with 
Roche, keeping the drug on the market.70
Nearly ten years later, the Roche post-marketing studies were 
published with data on the effectiveness of the FDA interventions.71  
The January 2000 issue of Morbidity and Mortality Weekly Report con-
veyed details of the Boston University Accutane Survey.72  The survey 
described 900 women who became pregnant while taking Accutane 
between 1989 and 1998, a rate of three pregnancies for every 1000 
treatments with the drug.73  In addition, the survey concluded a re-
duced pregnancy rate in 1998 of 2.1 pregnancies per 1000 females of 
child-bearing age versus in 1989 a rate of 4.0 per 1000.74  Therefore, 
one could infer that PPP was effective in lowering pregnancy rates 
among women of child-bearing potential using Accutane.  Difficulties 
with the study, however, caution against such a conclusion—the sur-
vey was voluntary and struggled to recruit females to participate—
 68 Memorandum from Dr. David J. Graham, Section Chief, Epidemiology Branch 
of the FDA to Dir., Div. of Anti-Infective Drug Prod., Dept. of Health and Human 
Serv. at 1 (May 7, 1990) (on file with FDA), available at http://energycommerce. 
house.gov/107/hearings/12112002Hearing755/12.pdf. 
 69 Id. at 2. 
 70 See id.; Memorandum from Bob Nelson, Member of Accutane Monitoring 
Group to Jim Bilstad, FDA Staff (Feb. 19, 1991), available at http://energycommerce. 
house.gov/107/hearings/12112002Hearing755/13.pdf (describing continuing 
communications between the FDA and Roche regarding Accutane monitoring); 
Mark D. Somerson, Memos Bare FDA Split Over Accutane, COLUMBUS DISPATCH, July 14, 
1996, at 7C (reporting that the FDA and Roche met twenty-three times between 1982 
and 1991 to discuss Accutane). 
 71 Accutane-Exposed, supra note 20, at 28–31 (reporting unpublished 1999 data 
from the Boston University Accutane Survey); Nelson, supra note 70, at 1–4 (report-
ing slow progress enrolling patients in the study probably due to it being a volunteer 
survey). 
 72 Accutane-Exposed, supra note 20, at 28–31. 
 73 Id. 
 74 Id. (data implies that PPP was effective in lowering the rate of pregnancies). 
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therefore it did not provide an accurate comparison of pregnancy 
rates.75
During this same time, Accutane’s popularity was growing expo-
nentially, largely due to Roche’s advertising as well as doctors over-
prescribing the medication.76  According to the Centers for Disease 
Control and Prevention’s study (“CDC study”), the number of “Accu-
tane prescriptions doubled from fewer than 750,000 prescriptions in 
1989 to more than 1,800,000 prescriptions in 1999” with around half 
of the prescriptions being written for women in both years.77  Fur-
thermore, the CDC study hypothesized that as Accutane use in 
women of child-bearing potential increases, more Accutane-exposed 
pregnancies can be expected.78
Through the Accutane survey and Roche Drug Safety database, 
the FDA compiled a review of individual pregnancy reports to un-
cover reasons for Accutane-exposed pregnancies.79  According to the 
prescriber tracking survey, ninety-seven percent of physicians used at 
least one component of the PPP.80  However, the FDA review uncov-
ered instances of patient confusion about timing of pregnancy tests,81 
patient misunderstanding of contraceptive methods, lack of monthly 
pregnancy testing and contraceptive counseling, and instances of pa-
tients receiving more than a month supply of medication.82  An 
evaluation of the reports also found the following reasons why 
women became pregnant: unsuccessful abstinence, ineffective or in-
consistent contraception use, unexpected sexual activity, and contra-
ceptive failure.83
 75 See Nelson, supra note 70, at 2–3.  Regardless of the study’s critiques, the FDA 
used three pregnancies per 1000 Accutane women patients as a factor in calculating 
success rates of risk management programs.  See Accutane-Exposed, supra note 20, at 26. 
 76 See M.A. Honein, L.J. Paulozzi & J.D. Erickson, Continued Occurrence of Accutane-
Exposed Pregnancies, 64 TERATOLOGY 142, 143 (2001). 
 77 Id. 
 78 Id. at 145. 
 79 See Leach, supra note 17. 
 80 Id. 
 81 Id.  The timing of a pregnancy test refers to the methods used to prevent false 
negatives.  Id.  This also includes having a woman wait, even if her pregnancy tests 
are negative, until her second or third day of menses before starting Accutane.  Id.  
This is another preventive measure taken to assure a woman is not pregnant.  Id. 
 82 Leach, supra note 17. 
 83 Id.  According to data presented which was based on the FDA reports and 
Roche’s database, fourteen percent of women were pregnant at the time of initial 
visit and twelve percent did not wait until the next menses before starting treatment.  
Id.  This suggests a failure in pregnancy testing.  In addition, the breakdown of preg-
nancy occurrences during therapy is the following:  Eleven percent “reported they 
believed they would be able to maintain abstinence”, thirty-four percent “reported 
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Also at this time, the FDA received individual case reports high-
lighting PPP’s ineffectiveness due to noncompliance among both pa-
tients and physicians.84  One report related to inappropriate prescrib-
ing by a physician to a thirty-five-year-old woman for the prevention 
of oily skin before menstruation.85  The physician did not counsel her 
about or recommend contraception.86  Though she used an intrauter-
ine device, she became pregnant after taking Accutane for three 
years.87  Because she had taken two doses of Accutane since her last 
menstrual period, she terminated the pregnancy, stating, “the sole 
reason for the decision was the exposure.”88  Another case involved a 
fifteen-year-old girl whose physician refilled her Accutane prescrip-
tion despite her having missed the required monthly pregnancy test.89  
Her pregnancy was confirmed at the next month’s appointment.90  
While the patient used oral contraception previously, she was not tak-
ing any during the time of the exposed pregnancy.91  The patient 
“elected to terminate the pregnancy, stating that Accutane exposure 
was a factor in her decision.”92
As a result of the post-marketing studies, analysis of the data, and 
various discussions, the FDA Dermatologic and Ophthalmic Drugs 
Advisory Committee on September 18, 2000, recommended that 
Roche integrate an additional five components into its risk manage-
ment program to further the FDA’s goal in eliminating pregnancy 
exposures among Accutane users: adopt a heightened educational 
program for each patient “that includes verifiable documented writ-
ten informed consent”; require “complete registration of all pa-
tients”; call for “complete registration and certification of practitio-
ners who prescribe Accutane”; devise a comprehensive program to 
track fetal exposures to Accutane (and outcomes), including a formal 
mandatory pregnancy registry; and “link dispensing of Accutane to 
failure to use contraception on the perceived day of conception” (thirty-three per-
cent of these patients were only using one form of contraception), and fifty-one per-
cent “reported contraception failure” (sixty-one percent of these patients were using 
one form of contraception).  Id.  
 84 See Honein, supra note 76, at 146; Accutane-Exposed, supra note 20, at 29. 
 85 Honein, supra note 76, at 147. 
 86 Id. 
 87 Id. 
 88 Id. 
 89 Id. 
 90 Id. 
 91 Honein, supra note 76, at 147. 
 92 Id. 
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female patients [to] verification of adequate pregnancy testing.”93  
Concerned about infringing privacy rights and creating too cumber-
some of a program,94 Roche only incorporated two of these sugges-
tions in its enhanced risk management program—S.M.A.R.T., System 
to Manage Accutane Related Teratogenicity.95
B. Risk Management from S.M.A.R.T. to iPLEDGE (2001-2005) 
The FDA approved the enhanced risk management program, 
S.M.A.R.T., in fall 2001, and the program was put into effect by April 
2002.96  The FDA announced two main goals of the S.M.A.R.T. pro-
gram: that no pregnant woman should begin Accutane therapy and 
“no pregnancies should occur while a woman is taking Accutane.”97  
The FDA indicated that even a single fetal exposure would be unac-
ceptable, yet both the Agency and Roche recognized that the goal of 
eliminating all fetal exposure might not be possible.98  The FDA did 
not set specific benchmarks in its approval of the program, but in-
stead informed Roche that “[t]he adequacy of S.M.A.R.T. will be a re-
view issue for re-evaluation on a continuing basis.”99  Emphasizing 
that Roche did not incorporate all of the FDA advisory committee 
recommendations,100 the Agency accepted this pregnancy prevention 
 93 Letter from Dr. Janet Woodcock, Dir., Ctr. for Drug Eval. and Research, to Dr. 
Russell Ellison, Chief Med. Officer, Vice President, Med. Affairs, Hoffman-La Roche, 
Inc. (Oct. 6, 2000), available at http://energycommerce.house.gov/107/hearings/ 
12112002Hearing755/24.pdf; Background of Isotretinoin, supra note 17, at 1. 
 94 Background of Isotretinoin, supra note 17, at 2. 
 95 See Hoffman-La Roche, Accutane Label Revision at 9–10 (Oct. 30, 2001) (on file 
with the FDA),  available at http://www.fda.gov/cder/foi/label/2001/ 
18662s44lbl.pdf; Letter from Dr. Jonathan K. Wilkin, Dir., Div. of Dermatologic & 
Dental Drug Prod., Ctr. for Drug Eval. and Research (CDER) to Joanna Waugh, 
Group Dir., Drug Regulatory Affairs, Hoffman-La Roche, Inc. (Oct. 30, 2001) (on file 
with the FDA), at 2, available at http://www.fda.gov/cder/foi/appletter/2001/ 
18662s44ltr.pdf. 
 96 Hoffman-La Roche, Accutane Label Revision (Oct. 30, 2001) (on file with the 
FDA), available at http://www.fda.gov/cder/foi/label/2001/18662s44lbl.pdf; see 
Background of Isotretinoin, supra note 17, at 3. 
 97 FDA Talk Paper, FDA Announces Changes to the Risk Management Program to Pre-
vent Birth Defects Caused by Accutane, http://www.fda.gov/bbs/topics/ 
ANSWERS/2001/ANS01113.html (last visited Jan. 9, 2007) [hereinafter Changes to 
Risk Management Program]. 
 98 Wilkin, supra note 95, at 2.  The FDA indicated that no threshold for the num-
ber of fetal exposure (greater than zero) would be acceptable during the first year of 
S.M.A.R.T.  Id.  
 99 Id. 
 100 See Background of Isotretinoin, supra note 17, at 2–3.  The manufacturer indi-
cated various reasons for its denial of the committee recommendations.  See id.  
These included rejecting a patient registry because of patient privacy issues, disagree-
ing with certifying physicians since the manufacturer felt it had no authority to cer-
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system contingent upon successful assessment studies, specifically 
mentioning achieving greater or equal to sixty percent enrollment in 
the volunteer patient survey of female patients and near 100% com-
pliance with the various program provisions.101
The S.M.A.R.T program was unique in its attempt to remedy 
noncompliance by both physicians and patients.  To address physi-
cians’ failure to obtain pregnancy testing, S.M.A.R.T. labeling of Ac-
cutane required that a woman of child-bearing potential have two 
negative pregnancy tests prior to starting treatment.102  To ensure 
compliance, doctors had to place yellow self-adhesive Accutane 
Qualification Stickers on Accutane prescriptions before a pharmacist 
could legally fill them.103  In order for a doctor to obtain these stick-
ers, physicians had to read an informational booklet about S.M.A.R.T. 
and return a completed Letter of Understanding to Roche confirm-
ing comprehension of the program requirements and Accutane’s risk 
in pregnancy.104  This qualification sticker step required physicians to 
assess Accutane patients before each new and refilled prescription.105
In addition, S.M.A.R.T. required patients to sign informed con-
sent forms containing warnings about fetal exposure to the drug.106  
Women of child-bearing potential had to commit to using two forms 
tify prescribers, and opposing a comprehensive program to track fetal exposures to 
Accutane because of privacy concerns.  See id. 
 101 Id. 
 102 Hoffman-La Roche, Accutane Label Revision (Oct. 30, 2001) (on file with the 
FDA), available at http://www.fda.gov/cder/foi/label/2001/18662s44lbl.pdf. 
     [Female patients of childbearing potential] [m]ust have had two 
negative urine or serum pregnancy tests with a sensitivity of at least 25 
mIU/mL before receiving the initial Accutane prescription.  The first 
test (a screening test) is obtained by the prescriber when the decision is 
made to pursue qualification of the patient for Accutane.  The second 
pregnancy test (a confirmation test) should be done during the first 
five days of the menstrual period immediately preceding the beginning 
of Accutane therapy.  For patients with amenorrhea, the second test 
should be done at least 11 days after the last act of unprotected sexual 
intercourse (without using 2 effective forms of contraception).  Each 
month of therapy, the patient must have a negative result from a urine 
or serum pregnancy test.  A pregnancy test must be repeated every 
month prior to the female patient receiving each prescription. 
Id. at 2–3. 
 103 Id. at 2.  The doctor must indicate on the sticker the patient’s gender, cut-off 
date for filling the prescription, and up to a thirty-day supply of the medication with 
no refills.  If the patient was a woman, the doctor must, in addition, write the date of 
qualification as determined from the last pregnancy test taken.  Id. 
 104 Id. 
 105 Id. 
 106 Hoffman-La Roche, supra note 102, at 2.   
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of effective contraception107 simultaneously unless they committed to 
“absolute abstinence.”108  Under this new program, all women under-
went monthly pregnancy tests while on Accutane therapy along with 
monthly consultation about contraception and behaviors associated 
with an increased risk of pregnancy.109  To track the program’s effec-
tiveness, the FDA required the manufacturer to conduct follow-up 
studies and to report the adequacy of the program to the Agency af-
ter the first year of implementation.110
Further complicating matters, by the time S.M.A.R.T. was put 
into effect in April of 2002, Roche’s patent had expired and two ge-
neric medications had entered the market.111  Amnesteem manufac-
tured by Genpharm was placed on the market on November 2002 
and Sotret, manufactured by Ranbaxy, was approved in December 
2002.112  Similar to Accutane, these forms of isotretinoin were ap-
proved with accompanying risk management programs, all possessing 
the essential elements of Accutane’s S.M.A.R.T. program.113  None-
theless, the medical community’s concern with the risk of Accutane-
exposed pregnancies increased as these more affordable generic ver-
sions became available.  A comment in a Canadian medical journal 
was typical: “[t]he introduction of generic forms of isotretinoin, to-
gether with decreasing prices, will further increase the use of this 
drug by sexually active women.”114
 107 Id. at 3.  Effective forms of contraception include both primary and secondary 
forms of contraception.  Primary forms include: tubal ligation, partner’s vasectomy, 
intra-uterine devices, birth control pills, and topical/implantable/insertable hormo-
nal birth control products.  Id.  Secondary forms of contraception include dia-
phragms, latex condoms, and cervical caps; each must be used with a spermicide.  Id. 
 108 Id.  “Absolute abstinence” is the wording taken directly from the package label, 
implying the patient will be compliant in her pledge to abstain from sexual inter-
course.  See id. 
 109 Hoffman-La Roche, supra note 102. 
 110 Id. at 10–12. 
 111 Gideon Koren, Marina Avner & Neil Shear, Generic Isotretinoin: A New Risk for 
Unborn Children, 170 CAN. MED. ASS’N J. 1567, 1567–68 (2004). 
 112 Id.;  Center for Drug Evaluation and Research, supra note 32. 
 113 Koren et. al., supra note 111.  Celegene, the manufacturer of Thalomid, 
branded Thalidomide and obtained patents for the creation of S.T.E.P.S.  Id.  In or-
der for Accutane and generic equivalents to use a similar risk management program, 
isotretinoin manufacturers licensed the risk management programs from Celegene.  
Id.  Without getting into patent infringement details, isotretinoin companies were 
able to form similar programs without the risk of infringing S.T.E.P.S.  Id. at 1568.  
These generic companies followed Hoffman-La Roche’s lead by adopting the essen-
tial elements of the S.M.A.R.T. system for their products.  Id. 
 114 Id. 
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These concerns proved valid.  The FDA estimated total actual 
pregnancy exposures during the first year of S.M.A.R.T. at 548.115  
The S.M.A.R.T. post-marketing survey results reported a pregnancy 
rate of 3.5 out of 1000 female patients of child-bearing potential.116  
In sum, the S.M.A.R.T. program did not achieve its two goals.  More 
strikingly, the pregnancy rates post-S.M.A.R.T. remained similar to 
the pre-S.M.A.R.T. rates.117
The House of Representatives Committee on Energy and Com-
merce addressed issues relating to Accutane safety on December 11, 
2002, hearing testimony about the benefits of the drug in cases of se-
vere acne along with reports regarding the drug’s horrific effect in 
pregnancy as well as alleged links to depression and suicide.118  Con-
gressional and media attention along with case reports of 
S.M.A.R.T.’s ineffectiveness prompted a joint meeting on February 26 
and 27, 2004, of the Dermatology and Ophthalmic Drugs and Drug 
Safety and Risk Management FDA Advisory Committees.119  The 
 115 Drs. Sidney M. Wolfe & Sherri Shubin, Pub. Citizen’s Res. Group, Presentation 
to the FDA Drug Safety and Risk Mgmt. and Dermatologic and Opthalmic Advisory 
Comms. (Feb. 26, 2004), available at http://www.fda.gov/ohrms/dockets/ac/ 
04/slides/4017OPH1_01_Wolfe.ppt.  This pregnancy exposure estimation is 4.6 
times higher than the 120 pregnancies spontaneously reported to the FDA.  Id.  Nu-
merical data used in the PowerPoint slide entitled “Estimation of Total Pregnancy 
Exposures During First Year S.M.A.R.T.” was taken from an FDA report.  Id. 
 116 Allen Brinker, Cynthia Kornegay & Parivash Nourjah, Trends in Adherence to a 
Revised Risk Management Program Designed to Decrease or Eliminate Isotretinoin-Exposed 
Pregnancies, 141 ARCH DERMATOLOGY 563, 568 (2005).  Enrollment for the S.M.A.R.T. 
post-marking survey began six months after the initiation of S.M.A.R.T.  Id. 
 117 Background of Isotretinoin, supra note 17, at 4. (“Regarding fetal exposures, 
although elimination of all exposures is the goal of the risk management program, it 
was understood that achievement of this might not be possible.  Hence no threshold 
for the number of fetal exposures (greater than zero) that would be ‘acceptable’ dur-
ing the first year of S.M.A.R.T. implementation was prespecified.”). 
 118 See Issues Related to the Safety of Accutane, supra note 33.  Representative Bart Stu-
pak of Michigan’s First Congressional District and member of the House Committee 
of Energy and Commerce lost his son to suicide in May of 2000.  His son was taking 
Accutane.  The FDA, in February of 1998, stated in a memorandum the adverse 
events that had been reported from the use of Accutane.  The memorandum showed 
that there were thirty-one cases of suicide, suicide attempt or suicide ideation that 
were associated with the use of Accutane. Of that number, twelve were suicides, nine 
of them male, two female, and one unknown, and the median age was seventeen. 
The average onset of the suicidal event was eighty-eight days after the patient had 
started on the prescribed use of Accutane.  As the FDA memorandum stated: “[f]or 
the majority, there was no antecedent history of depression, and the patients were 
not noted or known to be depressed at the time period prior to their suicide.”  Id. 
 119 Letter from Dr. Jonca Bull, Dir., Office of Drug Eval. of CDER & Dr. Anne 
Trontell, Deputy Dir., Office of Drug Safety of CDER, to Dermatology and Ophthal-
mic Drugs and Drug Safety and Risk Mgmt. Advisory Comm. members and guests 
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committees looked at prescription compliance and patient surveys, 
concluding that isotretinoin-exposed pregnancies continue to occur 
even after the implementation of S.M.A.R.T.120  While data from 
Roche showed better percentages in its patients and physicians’ com-
pliance, pregnancies continued to occur at an alarmingly high rate. 121  
With an observed pregnancy rate of 3.5 to 1000, it appeared that 
S.M.A.R.T.’s results were similar to those reported before the pro-
gram was put into place.122  One presenter summarized her view:
The S.M.A.R.T. program is clearly a failure. . . . It is time to end 
the more than twenty years of voluntary restrictions that have 
failed to reduce its prescribing for more than twenty times as 
many women as would be using the drug if it were limited to the 
approved indications.123
After reviewing the data, the advisory committees recommended 
strengthening the risk management program to include mandatory 
registration of all prescription recipients and to make a negative 
pregnancy test a condition to prescription dispensing for female pa-
tients who can become pregnant.124  Heeding the committees’ rec-
ommendation, Roche and generic companies created the iPLEDGE 
program.125  The FDA approved the program on August 15, 2005.126
(Feb. 2, 2004) (on file with FDA), available at http://www.fda.gov/ohrms/dockets/ 
ac/04/briefing/4017B100%20Bull%20Trontell%20cover%20letter%20.pdf. 
 120 FDA, Dermatology and Ophthalmic Drugs and Drug Safety and Risk Mgmt. 
Advisory Comm. (Feb. 26 2004), available at http://www.fda.gov/oc/advisory/ 
accalendar/2004/cder12535dd02262704.html. 
 121 Results from Accutane Survey—Abstracted from Roche Quarterly Report 
Submission (Jun. 30, 2002), available at http://energycommerce.house.gov/107/ 
hearings/12112002Hearing755/52.pdf.  The compliance data illustrates: signed con-
sent form ninety-five percent (compared to eighty-nine percent pre-S.M.A.R.T.), 
postponed Accutane until results of pregnancy test known eighty-nine percent 
(compared to seventy-eight percent pre-S.M.A.R.T.), postponed Accutane until next 
menstrual period fifty-one percent (compared to forty-six percent pre-S.M.A.R.T.), 
and pregnancy test taken prior to starting Accutane ninety-two percent (compared to 
eight-four percent pre-S.M.A.R.T.).  Id. 
 122 Dr. Allen Brinker, Isotretinoin Pregnancy Prevention Program Evaluation, 
Presentation to FDA (Feb. 26, 2004) (on file with FDA), available at 
http://www.fda.gov/ohrms/dockets/ac/04/slides/4017S1_07_Brinker.ppt. 
 123 See Wolfe & Shubin, supra note 115. 
 124 FDA, Dermatology and Ophthalmic Drugs and Drug Safety and Risk Mgmt. 
Advisory Comm. (Feb. 27 2004) (on file with FDA), available at http://www.fda.gov/ 
ohrms/dockets/ac/04/transcripts/4017T2.htm. 
 125 The companies filed a supplemental new drug application (SNDA) under 21 
CFR § 314.520, with restrictions to assure safe use.  This regulation acknowledges 
that while Accutane is safe and effective for some patients it imposes a risk to others.  
It also enables drug companies to keep their products on the market by restricting 
distribution of the drug to a patient population that will benefit from the drug’s 
therapeutic effectiveness while diminishing the occurrence of the drug’s side effect.  
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iPLEDGE, the third-generation of an Accutane risk management 
program, tracks the distribution of Accutane by requiring that only 
wholesalers registered with iPLEDGE can obtain isotretinoin from 
the manufacturers and only registered pharmacies can receive medi-
cation from these registered wholesalers.127  In addition, only doctors 
registered with the program can prescribe the medication.128  For pre-
scribers to register in the program, the doctor must agree to be re-
sponsible for pregnancy counseling of female patients of child-
bearing potential, as detailed in the guide for practitioners.129  Pre-
scribers also must obtain and enter patient information into the 
iPLEDGE system (via the internet or phone) before writing a pre-
scription.130  For women of child-bearing potential, the doctor must 
record monthly pregnancy test results, confirm that the patient re-
ceived monthly counseling, and enter the patient’s two chosen forms 
of contraception each month into the iPLEDGE database.131
Female patients of reproductive age must also register with the 
iPLEDGE program and access the system monthly to answer ques-
tions about the program requirements and to input their two chosen 
forms of birth control.132  These women also must sign a specific in-
formed consent about birth defects before starting isotretinoin ther-
apy.133  This form is in addition to the general informed consent form 
that all isotretinoin patients must sign.134  The informed consent per-
taining to birth defects is comprised of thirteen affirmative state-
21 C.F.R. § 314.520 (2000);  Letter from Dr. Florence Houn, Dir., Office of Drug 
Eval. III of CDER, to Ellen Carey, Senior Program Manager of Hoffman-La Roche 
(Aug. 12, 2005) (on file with FDA), available at http://www.fda.gov/ 
cder/foi/appletter/2005/018662s056ltr.pdf. 
 126 Letter from Dr. Florence Houn, supra note 125. 
 127 Center for Drug Evaluation and Research, Label of Accutane (Isotretinoin) 
NDA #018662 at 19, 23, http://www.fda.gov/cder/foi/label/2005/ 
018662s056lbl.pdf (last visited Jan. 9, 2007).  The iPLEDGE program is detailed in 
the label of Accutane as well as the generic equivalents.  iPLEDGE program website, 
https://www.ipledgeprogram.com/ (last visited November 16, 2006).  iPLEDGE is 
the risk management program for all isotretinoin products and therefore the 
iPLEDGE database is operated by a collaboration of these manufacturers.  Id. 
 128 Center for Drug Evaluation and Research, supra note 127, at 20–22. 
 129 Id. 
 130 Id. 
 131 Id.  The two forms of contraception mentioned include the choice of absti-
nence.  Id. 
 132 Id. at 23. 
 133 Center for Drug Evaluation and Research, supra note 127, at 23. 
 134 Id. at 23, 36–39.  There are twelve questions in the general informed consent 
where a patient must acknowledge the drug’s side effects.  The questions mainly per-
tain to reporting and identifying symptoms of depression while on the medication, 
and reading and understanding the patient educational material.  Id. at 36–39.  
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ments, next to which the patient must initial her name.135  Examples 
of these statements are: 
3.     I understand that I must avoid sexual intercourse completely, 
or I must use 2 separate, effective forms of birth control (contra-
ception) at the same time.  
. . .  
11.     I must stop taking isotretinoin right away and call my doctor if 
I get pregnant, miss my expected menstrual period, stop using 
birth control, or have sexual intercourse without using my 2 birth 
control methods at any time. 
12.     . . . If I become pregnant, I agree to be contacted by the 
iPLEDGE program and be asked questions about my pregnancy. I 
also understand that if I become pregnant, information about my 
pregnancy, my health, and my baby’s health may be given to the maker of 
isotretinoin and government health regulatory authorities.  . . .136
If such a patient is under eighteen, in addition to her signature, her 
parent or guardian and doctor must sign the form.137
II. THE SOCIAL AND SAFETY COSTS OF IPLEDGE 
iPLEDGE permits access to medication causing severe fetal de-
formities138 under the guise of a protective program but is in fact a 
counterproductive, inefficient, and intrusive monitoring system. In-
explicably, the FDA has continued to allow a medication to remain 
on the market with repeatedly inadequate risk management pro-
grams that fail to ameliorate the immense safety and social costs 
caused by Accutane.139  The FDA continues to treat the risk manage-
ment of Accutane like other drugs with similar risk management pro-
grams.  However, such an approach is inadequate because the patient 
population being treated with Accutane is much broader than other 
medications with similar risk management programs.140
 135 Id.  
 136 Id. at 37–38 (emphasis added). 
 137 Id. at 36. 
 138 Center for Drug Evaluation and Research, supra note 127, at 24.  
 139 See Background of Isotretinoin, supra note 17, at 1; Brinker, supra note 122.  
 140 See infra section II.B.  The FDA has approved risk management programs for 
other medications with the potential to cause birth defects.  Thalomid is FDA ap-
proved for the treatment of severe erythema nodosum leprosum, which is a form of 
leprosy occurring in immunocompromised patients. Celegene, Thalomid, 
http://www.thalomid.com/steps_program.aspx (last visited Jan. 9, 2007).  Since Tha-
lomid has a history of horrific side effects in fetuses, the drug is managed by 
S.T.E.P.S.  Id.  While S.T.E.P.S. requires pregnancy testing and use of oral contracep-
tion, it does not have detailed informed consents and follow-up procedures like 
iPLEDGE.  Id.  Another medication with a risk management program is Tracleer, 
FDA approved for the treatment of pulmonary arterial hypertension. Tracleer, 
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The FDA articulates an unwillingness to accept a greater than 
zero tolerance for pregnancy rates occurring with Accutane use, yet 
allows the drug’s existence on the market after continuously receiv-
ing reports of pregnancies under previous risk management pro-
grams.141  iPLEDGE will not eliminate fetal exposures to Accutane 
and it does not achieve the FDA’s desired balance between protecting 
future life and keeping an effective medication on the market.142  In 
fact, this program implements draconian measures aimed at prevent-
ing pregnancy but creates even more problems that should be unac-
ceptable to the FDA.  The social implications of the iPLEDGE provi-
sions on women of child-bearing potential will be explored first.  
Thereafter, a discussion of the safety costs associated with Accutane 
available on the market will be analyzed. 
A. The Social Cost of Impeding a Woman’s Autonomy in Medical 
Treatment Decisions 
Accutane’s availability through iPLEDGE promotes viewing 
women solely on their status as child bearers.  iPLEDGE limits 
women’s autonomy and defeats the purpose of having the medication 
on the market, to make available effective treatment to patients.143  
iPLEDGE improperly regulates a woman’s choice to bear children 
and take the risk of having children with birth defects.144  History il-
lustrates how profound a step backward iPLEDGE takes public policy 
and how high a social cost it generates. 
http://www.tracleer.com/ 
default.asp?page=OnTrac_WhatsTracleer (last visited Jan. 9, 2007).  Tracleer has a 
high potential for birth defects and is managed through a closed distribution system 
called the Tracleer Access Program (T.A.P.).  Tracleer, http://www.tracleer.com/ 
default.asp?page=HCP_Prescribe (last visited Jan. 9, 2007).  T.A.P. regulates patients’ 
access to the medication by centralizing the drug distribution to only four specialty 
pharmacies after a physician approves of its use in a patient.  Patient Enrollment—
T.A.P., http://www.tracleer.com/dot/TAP%20Patient%20Enrollment%20Form.dot 
(last visited Jan. 9, 2007). 
 141 See Changes to Risk Management Program, supra note 97. 
 142 Riepenhoff & Somerson, supra note 37.  Due to noncompliance issues, loop-
holes in the iPLEDGE program and illegal use of the medication, sexually active 
women could use isotretinoin and become pregnant.  Past risk management pro-
grams have failed.  See Wilkin, supra note 95.  iPLEDGE mandates will decrease in-
stances of abuse but will not eliminate them.  Perfection is impossible.  Id.; See Center 
for Drug Evaluation and Research, supra note 127. 
 143 See Center for Drug Evaluation and Research, supra note 127; Geraghty, supra 
note 27. 
 144 See Int’l Union v. Johnson Controls, Inc., 499 U.S. 187, 211 (1991). 
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i. The History of Limiting a Woman’s Autonomy Based 
on Her Childbearing Potential 
A woman’s autonomy is often compromised because of her po-
tential for pregnancy.  Individual autonomy is valued as a fundamen-
tal right derived from the Constitution and generally supersedes state 
actions restricting such personalized freedom.145  However, there are 
instances when even this well-protected and valued fundamental right 
of autonomy is sometimes limited.146  The government’s interest in 
women of child-bearing age is to protect the potential for future 
life.147  While this interest becomes heightened when a woman is 
pregnant and a fetus is viable, the interest is ambiguous when a 
woman’s rights are being limited solely based on her status as a 
woman of reproductive age.148  Without delving into a discussion of 
the various contexts where a maternal-fetal conflict149 arises, the fol-
lowing discussion will briefly highlight the treatment of women based 
on childbearing potential throughout history. 
Historically, courts would allow limiting women from employ-
ment opportunities based on being weak and fragile, existing only to 
serve a domestic role and bear children.150  Lawyers and lawmakers 
exploited perceived differences between the genders like intelli-
gence, behavior, physical appearance, social construct, hormonal 
makeup, and psychological characteristics as support for treating 
women differently.151  Ultimately, the differential treatment of women 
stemmed from their potential to bear children.152
 145 See generally CYNTHIA DANIELS, AT WOMEN’S EXPENSE: STATE POWER AND THE 
POLITICS OF FETAL RIGHTS 24 (Harvard Univ. Press 1993). 
 146 Id. at 15–35. 
 147 Id. 
 148 Id. 
 149 See generally Daniels, supra note 145, at 24.  This term refers to the relationship 
between a mother and fetus.  Id.  The federal government and various state govern-
ments have addressed situations where fetal rights outweigh a woman’s choice.  Id.  
In the context of forced medical intervention, criminal prosecution, and even abor-
tions, there are instances where the government will interfere with the choices of a 
mother to protect the fetus.  Id.  Since this discussion of the social cost of iPLEDGE 
concerns women not yet pregnant, a discussion of the maternal-fetal context would 
be too broad.  Id. 
 150 See Julianna S. Gonen, Removing Informed Consent from HIV Testing of Pregnant 
Women: A Return to the Maternal-Fetal Conflict, 2 GEO. J. GENDER & L. 765, 775–76 
(2001). 
 151 Id. at 775–77. 
 152 Id. 
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Bradwell v. Illinois153 illustrates a vivid portrayal of women treated 
as potential child bearers.  In Bradwell, the Supreme Court of the 
United States held that the right to practice law was not a privilege or 
immunity protected by the Fourteenth Amendment and denied a 
woman from obtaining a license to practice law.154  Justice Bradley in 
his concurrence wrote, “The paramount destiny and mission of 
women are to fulfill the noble and benign offices of wife and mother.  
This is the law of the Creator.  And the rules of civil society must be 
adapted to the general constitution of things, and cannot be based 
on exceptional cases.”155  Thirty-five years later, a similar portrayal of 
women appeared in the Supreme Court case Muller v. Oregon.156  This 
case denied establishing a maximum-hour law for male bakers since it 
interfered with the freedom to contract yet upheld such a law for 
women due to the government’s public interest in preserving the 
health of women.157  The Court further stated that even when a 
woman is not pregnant it is imperative to safeguard her health “as 
healthy mothers are essential to vigorous offspring, the physical well-
being of woman becomes an object of public interest and care in or-
der to preserve the strength and vigor of the race.”158
Title VII of the Civil Rights Act of 1964 changed the analysis of 
the above cases, prohibiting employment discrimination on the basis 
of race, color, religion, sex, and national origin.159  Soon afterwards, 
the Pregnancy Discrimination Act in 1978 was passed, extending the 
Title VII definition of “sex” to encompass pregnancy and related 
medical conditions.160  However, another debate began over “fetal 
protection policies” instituted by employers.161  These policies banned 
women of child-bearing potential from working with toxic substances 
that could affect or harm a developing fetus.162
 153 83 U.S. (16 Wall.) 130 (1873), abrogated by Planned Parenthood v. Casey, 505 
U.S. 833, 896 (1992).  
 154 Id. at 138–39.  
 155 Id. at 141–42 (1873) (Bradley, J., concurring). 
 156 Muller v. Oregon, 208 U.S. 412 (1908). 
 157 Id. at 420–22.  
 158 Id. at 421. 
 159 42 U.S.C. § 2000 (2000). 
 160 Id. at § 2000e. 
 161 See REGINA H. KENEN, REPRODUCTIVE HAZARDS IN THE WORKPLACE: MENDING JOBS, 
MANAGING PREGNANCIES 16 (Harrison Park Press 1993);  SALLY J. KENNEY, FOR WHOSE 
PROTECTION? REPRODUCTIVE HAZARDS AND EXCLUSIONARY POLICIES IN THE UNITED 
STATES AND BRITAIN 12 (University of Michigan Press 1992). 
 162 See KENEN, supra note 161, at 16; KENNEY, supra note 161, at 12. 
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In International Union v. Johnson Controls, Inc.163 the Supreme 
Court held that sex-specific fetal-protection policies are forbidden 
under Title VII of the Civil Rights Act.164  The case examined a battery 
manufacturing company’s policy of excluding women of reproductive 
age from jobs where lead exposure was possible.165  Though this case 
was determined in the context of employment-based discrimination, 
Justice Blackmun described the danger in treating all women of re-
productive age as pregnant.166  In addition, he mentioned that fetal 
safety was best left to the mother.167  Addressing the disparity in 
treatment between women of reproductive age and other employees 
of the battery company, Judge Blackmun explained that the law does 
not accept such discrimination under Title VII.168  The majority con-
cluded by maintaining that “[i]t is no more appropriate for the courts 
than it is for individual employers to decide whether a woman’s re-
productive role is more important to herself and her family than her 
economic role.  Congress left this choice to the woman as hers to 
make.”169
Despite Johnson Controls, companies continued instituting fetal-
protective polices.170  While some companies felt tort liability out-
weighed anti-discrimination suits by keeping fetal-protective policies 
in place, other companies refused to acknowledge the hazards to re-
production and evaluated situations on an individualized basis.171  
Even still, a few companies altered their policies to facially comply 
with Title VII.172  For example, the company Exide established a pol-
icy that required all women employees to attend a training session 
about lead exposure, which consisted of watching a video advocating 
that women should avoid jobs where exposure to lead was a possibil-
ity.173  The video also explained the adverse effects of lead exposure 
 163 499 U.S. 187 (1991). 
 164 42 U.S.C. § 2000 (2000). 
 165 Int’l Union v. Johnson Controls, Inc., 499 U.S. 187, 190 (1991). 
 166 Id. at 198. 
 167 Id. at 206. 
 168 Id. at 210. 
 169 Id. at 211. 
 170 See Elaine Draper, Reproductive Hazards and Fetal Exclusion Policies after Johnson 
Controls, 12 STAN. L. POL’Y REV. 117, 119 (2001);  Nicole G. Hoeksma, Regulating 
Risk: Reproductive Toxins in the Workplace in Post-Johnson Controls Era, 14 S. CAL. REV. L. 
& WOMEN'S STUD. 289, 289 (2005). 
 171 Draper, supra note 170, at 121. 
 172 Id. 
 173 Suzanne U. Samuels, The Lasting Legacy of International Union, U.A.W. v. John-
son Controls: Equal Employment and Workplace Health and Safety Five Years Later, 12 WIS. 
WOMEN’S L.J. 1, 8–9 (1997). 
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on reproduction. 174  Men working at the company were never made 
aware of these adverse affects.175
Pharmaceutical research is another area in which women of 
child-bearing potential were excluded and their health disadvantaged 
because of their gender.176  For years the FDA excluded women from 
clinical trials in order to protect reproductive capabilities.177  This at-
titude of “protectionism” stemmed from a desire to avoid prior re-
search abuse in what is frequently referred to as a “vulnerable” popu-
lation.178  However in 1993, President Clinton signed the National 
Institutes of Health Revitalization Act requiring the inclusion of 
women in clinical trials to ensure comprehensive analysis in re-
search.179  Consequently, the FDA policies were updated to encourage 
the inclusion of women participants, including those of reproductive 
age, in research studies.180  While the Agency has not mandated that 
drug companies include women of child-bearing potential, the FDA 
has acknowledged the benefit of studying medication effects on con-
senting women.181
While the employment and research contexts differ from the 
treatment context, the issues presented in Johnson Controls and in the 
FDA’s past research policies parallel issues that arise when a woman 
of reproductive age is subjected to the mandates of iPLEDGE.182  
iPLEDGE treats women of child-bearing potential differently than 
other patient populations.183  The program treats all women as preg-
nant regardless of their choice to bear children.184  Instead of allow-
ing a woman to make her own choices about contraception and the 
risk of pregnancy, the government and manufacturer dictate what a 
 174 Id. 
 175 Id. 
 176 See FDA, FDA Scholarship in Women’s Health Program, 
http://www.fda.gov/cber/clinical/femclin.htm (last visited Jan. 9, 2007) [hereinaf-
ter FDA Scholarship]; FDA, Executive Summary—Gender Studies in Product Devel-
opment, http://www.fda.gov/womens/gender/Exec4.htm (last visited Jan. 9, 2007) 
[hereinafter Executive Summary]. 
 177 See FDA Scholarship, supra note 176; Executive Summary, supra note 176. 
 178 See FDA Scholarship, supra note 176; Executive Summary, supra note 176. 
 179 See U.S. Department of Health and Human Services, National Institutes of 
Health, Revitalization Act of 1993, 42 U.S.C. § 289a-2 (2000). 
 180 See FDA Scholarship, supra note 176; Executive Summary, supra note 176. 
 181 See FDA Scholarship, supra note 176; Executive Summary, supra note 176.  In 
addition, studies do not separate differential side effects on men and women, so 
women still are not receiving the full benefit of pharmaceutical research. 
 182 See Draper, supra note 170, at 120. 
 183 See Center for Drug Evaluation and Research, supra note 127. 
 184 Id. 
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woman must do and use the iPLEDGE database to monitor compli-
ance before allowing access to the medication.185  While trying to at-
tain a zero pregnancy exposure rate to the drug, the FDA creates a 
restrictive program for women that may, as a result, encourage non-
compliance and increase the risk of Accutane-exposed pregnancies.186
ii. The Effect of iPLEDGE on Women of Reproductive 
Age 
The iPLEDGE program creates several obstacles for women of 
reproductive age before gaining access to the medication.187  While 
the program’s goal, to reduce the risk of fetal anomalies, is laud-
able,188 its methodology is flawed—the decisions of whether to be-
come pregnant, how to prevent pregnancy and what risks are reason-
able during pregnancy are the woman’s and hers alone.189  The FDA 
and drug manufacturers have an obligation to provide women with 
sufficient information to make educated decisions, but not to make 
the decisions for them.190  iPLEDGE’s imposition of restrictions on 
reproduction is overly inclusive in that it interferes with women’s 
autonomy based on their potential to become pregnant and their pre-
sumed sexual activity.191  The consequences of so circumscribing 
women’s behavior and choices in their medical treatment create 
more harm for fertile women than if the drug was simply unavailable.  
Treating women as pregnant or sexually active, when they are not, 
and making healthcare decisions on their behalf is a backwards and 
unacceptable step in public policy. 
iPLEDGE’s impingements on a woman’s freedom are both nu-
merous and onerous.  A woman of reproductive age must comply 
with several provisions in order to obtain a month’s supply of Accu-
tane.192  At her first doctor visit, she is counseled about the birth de-
fects that could occur if she becomes pregnant, receives a pregnancy 
test, is informed about registering for iPLEDGE through the elec-
tronic database, and undergoes consultation on contraception.193  
Regardless of her marital status, sexual orientation, personal view on 
 185 Id. 
 186 Id.  See supra section I.B. 
 187 See Center for Drug Evaluation and Research, supra note 127. 
 188 FDA Talk Paper, supra note 97. 
 189 See DANIELS, supra note 145; Int’l Union v. Johnson Controls, Inc., 499 U.S. 
187, 210 (1991). 
 190 See 21 C.F.R. §§ 201.56-.57 (2005). 
 191 See Center for Drug Evaluation and Research, supra note 127. 
 192 Id. at 23, 36–39. 
 193 Id. at 21–23, 25–26, 36–39.  
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sex outside of marriage or intention to have children, she receives in-
formation and is counseled about contraception.194
The potential Accutane patient must then read the consent 
forms, which require her to initial after statements dictating what she 
must do when engaging in sexual activity and when faced with a 
pregnancy.195  One statement requires her to tell the doctor at any in-
stance she breaks her commitment of abstinence or fails to use two 
forms of contraception during sexual activity.196
Afterward, the woman must return to her doctor for another 
visit to take a second pregnancy test, confirm her initiation of treat-
ment and receive an Accutane prescription that is voidable if not 
filled within seven days.197  Before filling the medication, the patient 
must input her two forms of contraception or commitment to absti-
nence into the iPLEDGE database and answer questions related to 
the program.198  This database can be accessed online or via tele-
phone, and a woman is expected to answer and input personal in-
formation into an automated system, with no personal contact with a 
healthcare professional.199  Only after inputting this information 
within the database is her prescription activated.200  She must then 
repeat this process for refills.201
These time-consuming and private steps disregard patient-
specific issues related to women of child-bearing age.202  Such steps 
deter women of reproductive age who genuinely could benefit from 
taking the medication from obtaining it.203  Below are examples of 
how this program unfairly treats women as “pregnant,” disregarding 
 194 Id. 
 195 Id. at 21–23, 36–39.  
 196 Id. at 38–39. 
 197 See Center for Drug Evaluation and Research, supra note 127, at 21, 38. 
 198 Id. at 23, 39.  No information is available on how detailed these questions will 
be or whether some questions might offend women who have pledged to abstain 
from sexual intercourse or minors.  See id.; iPLEDGE program website, supra note 
127. 
 199 See id. at 23, 46; iPLEDGE Program Frequently Asked Questions, 
http://www.fda.gov/cder/drug/infopage/accutane/FAQ200610.pdf (last visited 
Jan. 9, 2007) at 2–3. 
 200 See Center for Drug Evaluation and Research, supra note 127, at 23, 46; 
iPLEDGE Program Frequently Asked Questions, supra note 199, at 2–3. 
 201 Center for Drug Evaluation and Research, supra note 127, at 23, 38–39.  Nor-
mal duration of treatment is fifteen to twenty weeks, so refills are needed.  In order 
to obtain a refill prescription, a woman has to repeat all the program steps except 
signing the informed consent forms completed during her initial consultation.  Id. at 
15.  
 202 See supra notes 193–202.  
 203 Id. 
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their choices about reproduction and sexual activity in order to 
eradicate the possibility of pregnancy exposure to Accutane.  Conse-
quently, the premise of the program’s existence, to keep an effective 
acne treatment on the market, is expunged when patients who could 
benefit from its use do not have access to it.  As a result, noncompli-
ance becomes an easy alternative for these women to gain access, in-
creasing the possibility of Accutane-exposed pregnancies.204
1. A Woman Who Pledges Abstinence 
A vivid example of iPLEDGE disregarding female autonomy in 
health decisions related to reproduction and sex is the case of a 
woman or young teen who pledges abstinence by religious conviction 
or lifestyle choice.  Through iPLEDGE, she is still required to be 
counseled on contraception at the initial visit and monthly thereaf-
ter.205  She must also undergo initial and monthly pregnancy test-
ing.206  In addition, she is required to answer questions about the pro-
gram monthly that may relate to sexual activity.207  This government 
mandated program forces a woman to hear instruction about activi-
ties and preventative measures that may contradict her faith or per-
sonal preference. 
For example, the compelled use of two forms of contraception 
violates the religious beliefs of Catholics who adhere to church teach-
ings that they may only use natural family planning.208  Therefore, the 
program is an impediment for accessing isotretinoin.  While a patient 
unable to adhere to the conditions can always choose other acne 
treatments for nodular acne, isotretinoin is the most effective medi-
cation on the market.209  A woman who commits to abstinence is de-
terred from treatment by the program’s rigid and possibly offensive 
provisions.210  To subject such a woman to these mandates is bad pub-
lic policy because the program precludes her from exercising her 
choice to become pregnant and employs contraceptive approaches 
 204 See supra section I.B. 
 205 Center for Drug Evaluation and Research, supra note 127, at 21. 
 206 Id. 
 207 Id. 
 208 10 NEW CATH. ENCYCLOPEDIA 176–79 (Thomas Gale ed., Catholic University 
2003).  According to the labeling, natural family planning is not considered one of 
the options for contraception.  Center for Drug Evaluation and Research, supra note 
127, at 21–22, 37. 
 209 See Chorlton, supra note 45; Center for Drug Evaluation and Research, supra 
note 28 (approval occurred on May 7, 1982, which was a fast tracked approval due to 
the drug’s clinical effectiveness). 
 210 See supra notes 193–202.  
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that offend her religious beliefs.211  This program requires a woman 
who pledges abstinence to undergo additional pregnancy testing, 
doctor visits, and potentially offensive educational sessions.212
2. A Sexually Active Woman 
Another implication of iPLEDGE is the effect it has on sexually 
active women, treating them as potentially pregnant.  A woman who 
engages in sexual intercourse should not be compelled to forego 
health decisions regarding sex and reproduction as a condition of 
having access to medical care.  To obtain Accutane, a woman en-
gaged in sexual activity must use two forms of contraception.213  This 
limits the woman’s choices regarding her own health.  For example, 
if a woman does not agree with or has difficulty with taking hormonal 
contraception, she may be prevented from access to Accutane.214
If a woman elects to take Accutane, which requires her to con-
sent to iPLEDGE provisions, but then chooses for whatever reason 
not to comply with the contraception requirements, or has a contra-
ceptive failure and becomes pregnant, she must include the 
iPLEDGE program in discussions regarding her personal choices.215  
By the program’s involvement in tracking the pregnancy216 and pro-
viding educational services, a woman’s decision about reproduction 
may be influenced by a governmentally approved program.  Usually 
the woman and her doctor discuss this decision.  The fear of involv-
ing an unwanted but interested third party creates the potential for 
abuse in affecting a person’s choice.  A possible concern here could 
be an opportunity for the program or the FDA to advocate for abor-
tions, thereby reducing the number of birth defects and pregnancy 
exposures to Accutane and keeping the drug on the market.  While 
only a possibility, the involvement of individuals other than those 
whom the woman chooses raises concerns about the type of informa-
tion provided to, and influences imposed upon, the patient. 
3. A Female Minor of Child-bearing Age 
Similarly, a female minor of reproductive age may be discour-
aged from obtaining treatment due to implications regarding paren-
tal consent.  A female patient of child-bearing age, but under the age 
 211 See Int’l Union v. Johnson Controls, Inc., 499 U.S. 187, 200 (1991).  
 212 See Center for Drug Evaluation and Research, supra note 127, at 21–22, 37, 39. 
 213 Id. 
 214 Id. 
 215 Id. at 39.  
 216 Id.   
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of eighteen, must have her guardian or parent and doctor sign the 
iPLEDGE informed consent forms before initializing acne treat-
ment.217  This requires a minor not only to discuss issues regarding 
her sexual activity and views on reproduction with her doctor but also 
with her parent(s).  In addition, a minor is exposed to Accutane 
counseling on contraception218 that may be offensive to the patient or 
her parent(s).  Such provisions can limit or deter access to the medi-
cation at a time in life when its psychological and social benefits are 
likely most acute.  Furthermore, many state laws allow minors to re-
ceive sexual health treatment without parental consent, so the 
iPLEDGE provisions may pose a problem in requiring parents or 
guardians to sign consent forms authorizing acne treatment, which 
include the disclosure of use of contraception.219 
iii. Overall Social Cost of iPLEDGE 
The program’s effect on women of reproductive age takes a 
backward step in public policy, treating women based on their poten-
tial to become pregnant.  The FDA clearly seeks to further the laud-
able goal of protecting future life.  While this argument has been 
used in employment cases where environmental exposure effects 
women’s reproductive organs, Accutane exposure is harmful to a fe-
tus.220  As a result, the FDA’s goal in limiting treatment for women of 
child-bearing age implies that women and their doctors cannot make 
decisions regarding reproduction and sexual health without the in-
volvement of a third party, the iPLEDGE program.  This assumption 
interferes with the traditional patient-physician decision-making rela-
tionship, diminishes a woman’s choice, and creates a potential for 
abuse by the manufacturer. 
Consequently, the goal of the program’s existence, to keep an 
effective acne treatment on the market,221 is lost when patients who 
could benefit from its use do not have access to it.  The social ex-
pense of iPLEDGE described above highlights the cost of interfering 
with personal autonomy.  Another problem with the iPLEDGE pro-
gram is limiting a patient’s access to medication, which creates the 
 217 Center for Drug Evaluation and Research, supra note 127, at 36, 39.  
 218 Id. at 20–21, 25, 38–39.  
 219 See Rachel K. Jones, Confidential Reproductive Health Services for Minors: The Poten-
tial Impact of Mandated Parental Involvement for Contraception, 36 PERSP. ON SEXUAL & 
REPROD. HEALTH 182, 186–87 (2004). 
 220 Center for Drug Evaluation and Research, supra note 127, at 11–12, 51–54. 
 221 See Marilyn R. Pitts, FDA Safety Evaluator, Presentation at the American Society 
of Health-System Pharmacists Clinical Midyear (Dec. 7, 2005), available at 
http://www.ashp.org/emplibrary/RiskManagementPlans.pdf. 
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potential for abuse and subsequently unsafe use of medication.  The 
next section illustrates how possibilities of abuse or noncompliance 
create safety concerns that outweigh the effectiveness of the Accu-
tane. 
B. The Safety Cost: Weighing the Risks and Benefits of Accutane 
Congress requires the FDA to consider safety before it approves 
a new drug for market introduction.222  A manufacturer must demon-
strate safety with sufficient evidence when submitting a New Drug 
Application.223  While Accutane was approved by the FDA as safe and 
effective in 1982, post-marketing analysis of the risk of pregnancy ex-
posure to the drug prompted the introduction of a risk management 
program as a condition of keeping the medication on the market.  
Unfortunately, neither past programs nor iPLEDGE have or will 
eliminate pregnancy exposures.  Therefore, the safety cost of Accu-
tane being available on the market is too great to justify its benefit as 
an effective acne treatment. 
The FDA bases pre-market approval of an NDA on a risk-benefit 
analysis “for the intended population and use.”224  The importance of 
considering the intended population with the side effects of a medi-
cation is to assess the rate of risk.  For example, Thalomid (thalido-
mide) and Tracleer, which both cause severe birth defects in preg-
nant patients, are prescribed to a much narrower patient population 
than Accutane.225  Therefore the ability for this risk management pro-
gram to be effective is decreased when there is a broader patient 
 222 21 U.S.C.A. § 355(d) (West 2006).  The term safe refers to “health of man or 
animal.”  21 U.S.C.A. § 321 (West 2006) (“Safe” was intended to include only the in-
herent safety of drug when used in the manner intended.). 
 223 21 U.S.C.A. § 355. 
 224 FDA, Managing the Risks From Medical Product Use: Creating A Risk Man-
agement Framework at 21, http://www.fda.gov/oc/tfrm/riskmanagement.pdf (last 
visited Jan. 3, 2007) [hereinafter Managing the Risks]. 
 225 See Celgene, Thalomid, supra note 140; Tracleer, supra note 140.  Thalomid 
treats multiple myeloma and severe erythema nodosum leprosum while Tracleer 
treats pulmonary arterial hypertension.  See Celgene, Thalomid, supra note 140; Tra-
cleer, supra note 140.  These conditions occur in patient populations that are gener-
ally focused on fewer patients and older patients than Accutane’s intended popula-
tion—adolescents and adults with severe forms of acne.  See Celgene, Thalomid, 
supra note 140; Tracleer, supra note 140.  The risk of pregnancy in pre-menopausal, 
sexually active patients creates a greater risk than in patient populations with that are 
postmenopausal, immunocompromised and physically impaired by their health con-
dition, as is generally the situation with patients being treated with Thalomid and 
Tracleer.  See Celgene, Thalomid, supra note 140; Tracleer, supra note 140.  Also, nei-
ther Thalomid nor Tracleer is available in generic forms, thereby economically limit-
ing patients from access to these therapies as well.  See Celgene, Thalomid, supra note 
140; Tracleer, supra note 140. 
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population within the age range to become pregnant using the medi-
cation.  Thalomid and Tracleer have a greater potential to meet the 
FDA’s zero pregnancy threshold goal since the number of patients 
being treated with the medication are less likely to be as sexually ac-
tive or able to conceive compared to Accutane patients.226  Thus, the 
Thalomid and Tracleer risk management programs have the ability to 
manage the risk of birth defects, while iPLEDGE has a much harder 
task. 
The Agency acknowledges a safe product as one with “reason-
able risks, given the magnitude of the benefit expected and the alter-
natives available.”227  However, no drug is without side effects.228  The 
amount of risk acceptable in light of a drug’s beneficial effect re-
mains difficult to calculate.229  Clinical trials can establish scientific 
data to illustrate whether a product is safe but such data does not 
conclusively suggest the value judgment that ultimately must be made 
as to the safety of a drug.230  “[S]cience alone can never be an ade-
quate basis for a risk decision . . . risk decisions are, ultimately, public 
policy choices.”231
Keeping a beneficial medication available to patients by manag-
ing its side effects is good public policy.  However, the ability to man-
age the side effects is key for this analysis.  Risk assessment in phar-
maceuticals involves the evaluation and analysis of risks associated 
with a drug product.232  Most risk management programs encompass 
the following key components: identification of the problem, analysis 
 226 See Celgene, Thalomid, supra note 140; Tracleer, supra note 140. 
 227 See Managing the Risks, supra note 224, at 3. 
 228 See Celgene, Thalomid, supra note 140; Tracleer, supra note 140. “Although 
medical products are required to be safe, safety does not mean zero risk, since all 
medical products are associated with risks.”  Managing the Risks, supra note 224, at 3. 
 229 In unsuccessful legislation, the FDA sought to define the term safe; “the term 
‘safe’ means that the health benefits of the drug entity clearly outweigh the risks pre-
sented by the drug entity, taking into account the standards and requirements appli-
cable to drug products . . . .” James T. O’Reilly, 1 FOOD AND DRUG ADMIN. §14:4, n.14 
(quoting S. 1045, 96th Cong. (1979); S. 2755, 95th Cong. §109(E) (1978)). 
 230 See Managing the Risks, supra note 224. 
 231 NATIONAL RESEARCH COUNCIL, UNDERSTANDING RISK: INFORMING DECISIONS IN A 
DEMOCRATIC SOCIETY 26 (1996). 
 232 FETTERMAN, supra note 1, at 116. 
     Risk Assessment: as it relates to healthcare, scientific evaluation of 
known or potential adverse health effects resulting from human expo-
sure to medication therapies.   
     Risk management: the systematic approach to setting the best 
course of action, policies, processes, procedures, practices, and re-
sources to the assessment, communication and control of risk issues af-
fecting human health and safety. 
Id. 
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of the probability and severity of the risk, planning and communicat-
ing to control the risk, and evaluating the outcomes of interven-
tions.233
The early stages of Accutane use in clinical trials illustrate the 
start of a public policy debate over whether the benefits of a miracu-
lous acne treatment outweigh the drug’s risk in causing fetal deformi-
ties.  In the beginning, Accutane’s benefits outweighed its known risk 
in pregnancy exposure.234  No other medication on the market cured 
this degree of acne like Accutane.235  In addition, the FDA never iden-
tified Accutane’s devastating effect in human pregnancy during the 
pre-market approval phase.236
Not until post-marketing studies and voluntary patient reporting 
did the FDA identify human birth defects as an unacceptable risk of 
Accutane use.237  Lack of complete data impaired the FDA’s full as-
sessment of the problem.238  As a result, the Agency and manufacturer 
delayed implementing risk controls in order to understand where to 
attack the problem of exposure in pregnancy.239  After gathering data 
and observing case reports of babies born with abnormalities, the 
FDA conditioned Accutane’s continued sales on a zero pregnancy 
exposure policy.240  The FDA would not compromise with Roche dur-
ing the pre-S.M.A.R.T. time period to set a threshold limit on preg-
nancy exposure, apparently in conformity with the Agency’s policy 
against harming future life.241
Nonetheless, even with the implementation of the S.M.A.R.T. 
program, pregnancies still occurred as a result of noncompliance in 
the broad patient population being treated with the medication.242  
This led to discussions regarding the creation of iPLEDGE.243  With 
the approval of iPLEDGE the FDA pronounces that Accutane can be 
used safely, but only under restrictive distribution. 244  The FDA has 
 233 Id. at 68–69. 
 234 See Background of Isotretinoin, supra note 17, at 1. 
 235 Id.  Accutane has been referred to as a “miracle drug” for its effectiveness in 
the treatment of severe acne. See Issues Related to the Safety of Accutane, supra note 33 
(statement by Dr. Diana S. Berson, Associate Director of Dermatology at Cornell 
University). 
 236 Riepenhoff & Somerson, supra note 37. 
 237 See id.  
 238 See id. 
 239 See id. 
 240 See Wilkin, supra note 95. 
 241 Id. 
 242 Mitchell et al., supra note 59, at 101–06; Leach, supra note 17. 
 243 Center for Drug Evaluation and Research, supra note 127. 
 244 See 21 C.F.R. § 314.520 (2000). 
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not attained its goal of zero pregnancy exposures, and fails to ac-
knowledge the impossibility of obtaining complete patient adherence 
to any risk management program.  Since physicians may legally pre-
scribe drugs for off-label uses, it is not possible to ensure physician 
compliance to limit prescriptions only to the most severe acne cases. 
While a deviation from the program could invoke regulatory sanc-
tions and other actions, punishing a pregnant woman for conceiving 
under iPLEDGE is harsh and impractical.245   
While well-intentioned, the FDA is compromising public health.  
If past risk management programs were not successful in preventing 
exposed pregnancies, the use of a mandatory registry will not stop 
those patients too embarrassed to report their diversions to iPLEDGE 
from defying the program’s mandates.  The restrictive provisions of 
the program will not just deter women from taking the medication 
but may encourage the program’s failure.  Women of reproductive 
age who are sexually active may lie in their responses to the iPLEDGE 
database.  Minors may feel great pressure to be dishonest in discus-
sions with their parents or guardians, fail to reveal they are sexually 
active, and begin medication without any contraception.  This in-
creases the chance of an Accutane-exposed pregnancy. 
Exposed pregnancies are inevitable with a medication treating a 
broad patient population, suggesting that the safe use of the isotreti-
noin is impossible.  The FDA is simply attempting to avoid this immu-
table reality by affirming a third-generation risk management pro-
gram for isotretinoin.  Allowing a woman to face the horrible choice 
of having an unwanted abortion or a child with birth deformities due 
to drug exposure outweighs the need for clear skin even in the most 
severe cases of acne. 
III.     CONCLUSION 
The FDA’s unwillingness to protect future life by taking Accu-
tane off the market (a true zero tolerance of pregnancy rates) has 
simply gone on too long.  As long as Accutane remains on the mar-
ket, the goal of eliminating all fetal exposures will never be at-
tained.246  And yet, in pursuit of this flawed goal, iPLEDGE improp-
erly limits women’s autonomy through intrusive and ineffective 
 245 Center for Drug Evaluation and Research, supra note 127, at 38–39.  As the 
U.S. News and World Report commented, “[a]n irresponsible pregnancy, once just a 
source of shame, will soon be a recordable national offense—that is if it occurs while 
taking the acne drug Accutane.”  Bernadine Healy, Pledging for Accutane, U.S. NEWS & 
WORLD REP., Sept. 5, 2005, at 63. 
 246 See Pitts, supra note 221. 
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provisions that are so strict that they actually encourage noncompli-
ance.247  The result of nonadherence is pregnancy exposure and the 
possibility of regulatory action punishing the patient.  Instead of sim-
ply withdrawing the medication, the FDA limits the choice of a 
woman based on her potential to become pregnant in the hopes that 
this will eliminate pregnancy exposures. 
The FDA’s indecision incurs social and safety costs.  Yet, the FDA 
has chosen to allow Accutane to remain on the market since 1982 
with evidence of continued pregnancy exposures and birth defects in 
children.  Dr. David J. Graham of the FDA stated, “Isotretinoin is one 
of five dangerous drugs that should be removed from the market.”248  
The FDA, upon due notice to the manufacturer, has the statutory au-
thority to immediately withdraw a product from the market by revok-
ing the product’s NDA on the grounds that the drug is an “imminent 
hazard” to the public health.249  The FDA chooses iPLEDGE as the so-
lution instead of making a tough decision regarding the value of pre-
venting fetal exposure to Accutane.  As a result, iPLEDGE “will bring 
guilt, lies, and misdemeanors but no fewer pregnancies or conse-
quent abortions.”250  The FDA should take action and remove Accu-
tane from the market before further pregnancy exposures occur. 
 247 Center for Drug Evaluation and Research, supra note 127. 
 248 See Issues Related to the Safety of Accutane, supra note 33 (statement by Dr. 
David J. Graham of the FDA). 
 249 O’REILLY, supra note 229, at §13:23.  The Agency can also remove the drug 
from the market if: 
1.  The drug has been found unsafe under its labeled conditions of use, 
upon experience, tests or other scientific data 
2.  New evidence shows that the drug is not safe for its intended and 
labeled use 
3.  New information shows a lack of substantial evidence of effective-
ness 
4.  The approved application is found to have an untrue statement of a 
material fact.   
Id. 
 250 Healy, supra note 245, at 63. 
